Arif, "Extraneuronal activities and regulatory mechanisms of the atypical cyclin-dependent kinase
Cdk5," Biochemical Pharmacology, vol.
Sheldrake et al., "The cyclin-dependent kinase
inhibitor R-roscovitine down-regulates Mcl1 to override pro-inflammatory signalling and drive neutrophil apoptosis," European Journal of Immunology, vol.
Harlow, "Distinct roles for cyclin-dependent kinases
in cell cycle control," Science, vol.
Noble, "Structure-based design of cyclin-dependent kinase
inhibitors," Pharmacology and Therapeutics, vol.
Takeda et al., "Neuron-specific phosphorylation of Alzheimer's [beta]-amyloid precursor protein by cyclin-dependent kinase
5, " Journal of Neurochemistry, vol.
(28.) Malumbres M, Barbacid M: Mammalian cyclin-dependent kinases
. Trends Biochem Sci 2005; 30: 630-641
regulate the antiproliferative function of Smads.
p27 is regarded as a cyclin-dependent kinase
inhibitor of the G1-to-S cell cycle progression by suppressing the kinase activity of cyclin/cyclin-dependent kinase complex.
Some of the non-biological drugs, known as Cyclin-dependent kinase
(CDK) inhibitors, are currently being tested for use in cancer treatment.
"Altered prostatic epithelial proliferation and apoptosis, prostatic development and serum testosterone in mice lacking cyclin-dependent kinase
inhibitors," Biology of Reproduction 73(5): 951-958.
Melanoma and breast cancer are fairly common bedfellows in familial cancer syndromes, and both types of cancer have been linked with mutations in cyclin-dependent kinase
inhibitor 2A, a tumor suppressor gene, in some studies of familial cancer cohorts.
Acting as a transcription factor the tetramer causes the production of protein p21 in complex with cyclin-dependent kinase
(cdk2) which prevents the cell from entering the next stage of cell division (Kubbutat et al., 1998).
STRUCTURAL STUDIES OF CYCLIN-DEPENDENT KINASE
INHIBITORS: DYNAMICS AND FLEXIBILITY ARE THE STORY.
Japan-based global pharmaceutical company, Eisai, announced yesterday that new data from a real world observational study of the use of eribulin mesylate injection (marketed as HALAVEN(R)) following cyclin-dependent kinase
(CDK) 4/6 inhibitor in community oncology practices will be presented during the 36th Miami Breast Cancer Conference (MBCC).
Syros Pharmaceuticals announced that it will present new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase
7 inhibitor currently in a Phase 1 clinical trial focused on ovarian and breast cancers, and on SY-5609, its selective oral CDK7 inhibitor that the company has named as its next development candidate, at the American Association for Cancer Research Annual Meeting taking place March 29-April 3 in Atlanta.